Junan Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7363456/publications.pdf

Version: 2024-02-01

| | | 687363 | 361022 |
|----------|----------------|--------------|----------------|
| 39 | 1,298 | 13 | 35 |
| papers | citations | h-index | g-index |
| 39 | 39 | 39 | 2585 |
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|----|---|--------------|-----------|
| 1 | A Single Nucleotide Polymorphism (SNP) in the <i>SLC22A3</i> Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy. Anticancer Research, 2022, 42, 385-395. | 1.1 | 4 |
| 2 | CRISPR/Cas9 Genome Editing of the Human Topoisomerase II <i>α</i> Intron 19 5′ Splice Site Circumvents Etoposide Resistance in Human Leukemia K562 Cells. Molecular Pharmacology, 2021, 99, 226-241. | 2.3 | 9 |
| 3 | Synthesis and Antileishmanial Evaluation of Arylimidamide–Azole Hybrids Containing a Phenoxyalkyl Linker. ACS Infectious Diseases, 2021, 7, 1901-1922. | 3.8 | 3 |
| 4 | Educating Pharmacy Students About Underserved Populations Using Patient Speakers and Simulation Activities. American Journal of Pharmaceutical Education, 2021, 85, 8461. | 2.1 | 6 |
| 5 | Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy. Nature Communications, 2021, 12, 7264. | 12.8 | 55 |
| 6 | Synthesis and antileishmanial evaluation of thiazole orange analogs. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126725. | 2.2 | 14 |
| 7 | PTC209, a Specific Inhibitor of BMI1, Promotes Cell Cycle Arrest and Apoptosis in Cervical Cancer Cell Lines. Anticancer Research, 2020, 40, 133-141. | 1.1 | 8 |
| 8 | Cisplatin Induced the Expression of SEI1 (TRIP-Br1) Oncogene in Human Oral Squamous Cancer Cell Lines. Anticancer Research, 2020, 40, 67-73. | 1.1 | 0 |
| 9 | Antiemetic medication efficacy during EPOCH and R-EPOCH treatment. Journal of Oncology Pharmacy Practice, 2020, 27, 107815522096772. | 0.9 | 1 |
| 10 | Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. Anticancer Research, 2020, 40, 5707-5713. | 1.1 | 4 |
| 11 | XRCC1â€mediated DNA repair is associated with progressionâ€free survival of multiple myeloma patients after autologous stem cell transplant. Molecular Carcinogenesis, 2019, 58, 2327-2339. | 2.7 | 7 |
| 12 | Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer. Nano Research, 2019, 12, 855-861. | 10.4 | 39 |
| 13 | Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience. Leukemia and Lymphoma, 2019, 60, 2223-2229. | 1.3 | 12 |
| 14 | A Single Nucleotide Polymorphism in <i>SLC7A5</i> Was Associated With Clinical Response in Multiple Myeloma Patients. Anticancer Research, 2019, 39, 67-72. | 1.1 | 10 |
| 15 | Microneedle-Based Delivery of Amphotericin B for Treatment of Cutaneous Leishmaniasis. Biomedical Microdevices, 2019, 21, 8. | 2.8 | 18 |
| 16 | Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies. Leukemia and Lymphoma, 2018, 59, 2377-2382. | 1.3 | 13 |
| 17 | A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine. Journal of Oncology Pharmacy Practice, 2018, 24, 290-298. | 0.9 | 8 |
| 18 | Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3 . 2 | 10 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | antification of miRNAs Co-Immunoprecipitated with Argonaute Proteins Using SYBR Green-Based -PCR. Methods in Molecular Biology, 2018, 1680, 29-40. | | 4 |
| 20 | Pharmacokineticâ€Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving Highâ€Dose Melphalan for Autologous Stem Cell Transplant. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 748-758. | 2.5 | 11 |
| 21 | Efficacy of Once-Weekly Bortezomib with Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2018, 132, 1958-1958. | 1.4 | O |
| 22 | Polymorphism in <i>ANRIL</i> is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Molecular Carcinogenesis, 2017, 56, 1722-1732. | 2.7 | 28 |
| 23 | G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. Leukemia and Lymphoma, 2017, 58, 2947-2951. | 1.3 | 4 |
| 24 | Increased complement activation during platelet storage. Transfusion, 2017, 57, 2182-2188. | 1.6 | 21 |
| 25 | Deletion of RDINK4/ARF enhancer: A novel mutation to "inactivate―the INK4-ARF locus. DNA Repair, 2017, 57, 50-55. | 2.8 | 7 |
| 26 | Age-dependent accumulation of mitochondrial DNA deletions in the aortic root of atherosclerosis-prone apolipoprotein E-knockout mice. Archives of Gerontology and Geriatrics, 2016, 63, 72-77. | 3.0 | 8 |
| 27 | Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Scientific Reports, 2015, 5, 12122. | 3.3 | 58 |
| 28 | Alterations in RD INK4/ARF -mediated en bloc regulation of the INK4-ARF locus in human squamous cell carcinoma of the head and neck. Molecular Carcinogenesis, 2015, 54, 532-542. | 2.7 | 9 |
| 29 | Genetic alterations of <i>RD</i> <isink4 arf<="" i=""> enhancer in human cancer cells. Molecular Carcinogenesis, 2014, 53, 211-218.</isink4> | 2.7 | 15 |
| 30 | Coordinated expression of cyclin-dependent kinase-4 and its regulators in human oral tumors. Anticancer Research, 2014, 34, 3285-92. | 1,1 | 5 |
| 31 | Regulatory Mechanisms of Tumor Suppressor P16 ^{INK4A} and Their Relevance to Cancer. Biochemistry, 2011, 50, 5566-5582. | 2.5 | 251 |
| 32 | Gankyrin, a biomarker for epithelial carcinogenesis, is overexpressed in human oral cancer. Anticancer Research, 2011, 31, 2683-92. | 1.1 | 25 |
| 33 | Gankyrin Oncoprotein: Structure, Function, and Involvement in Cancer. Current Chemical Biology, 2010, 4, 13-19. | 0.5 | 5 |
| 34 | Tumor suppressor <i>p16</i> ^{<i>INK4A</i>} / <i>Cdkn2a</i> alterations in 7, 12â€dimethylbenz(a)anthracene (DMBA)â€induced hamster cheek pouch tumors. Molecular Carcinogenesis, 2008, 47, 733-738. | 2.7 | 10 |
| 35 | Ankyrin Repeat: A Unique Motif Mediating Proteinâ^'Protein Interactionsâ€. Biochemistry, 2006, 45, 15168-15178. | 2.5 | 537 |
| 36 | A Structurally Optimized Celecoxib Derivative Inhibits Human Pancreatic Cancer Cell Growth. Journal of Gastrointestinal Surgery, 2006, 10, 207-214. | 1.7 | 25 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Dissection of CDK4-Binding and Transactivation Activities of p34SEI-1and Comparison between Functions of p34SEI-1and p16INK4Aâ€. Biochemistry, 2005, 44, 13246-13256. | 2.5 | 25 |
| 38 | Expression and characterization of Syrian golden hamster p16, a homologue of human tumor suppressor p16INK4A. Biochemical and Biophysical Research Communications, 2003, 304, 241-247. | 2.1 | 8 |
| 39 | Frequent p16INK4A/CDKN2A alterations in chemically induced Syrian golden hamster pancreatic tumors. Carcinogenesis, 2003, 25, 263-268. | 2.8 | 21 |